Literature DB >> 7579712

Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity.

K Goishi1, S Higashiyama, M Klagsbrun, N Nakano, T Umata, M Ishikawa, E Mekada, N Taniguchi.   

Abstract

Vero cell heparin-binding epidermal growth factor-like growth factor (HB-EGF) is synthesized as a 20- to 30-kDa membrane-anchored HB-EGF precursor (proHB-EGF). Localization and processing of proHB-EGF, both constitutive and 12-O-tetradecanoylphorbol 13-acetate (TPA)-inducible, was examined in Vero cells overexpressing recombinant HB-EGF (Vero H cells). Flow cytometry and fluorescence immunostaining demonstrated that Vero cell proHB-EGF is cell surface-associated and localized at the interface of cell to cell contact. Cell surface biotinylation and immunoprecipitation detected a 20- to 30-kDa heterogeneous proHB-EGF species. Vero H cell surface proHB-EGF turned over constitutively with a half-life of 1.5 h. Some of the 20- to 30-kDa cell surface-associated proHB-EGF was processed and a 14-kDa species of bioactive HB-EGF was released slowly, but most of the proHB-EGF was internalized, displaying a diffuse immunofluorescent staining pattern and accumulation of proHB-EGF in endosomes. Addition of TPA induced a rapid processing of proHB-EGF at a Pro148-Val149 site with a half-life of 7min. The TPA effect was abrogated by the protein kinase C inhibitors, staurosporine and H7. Kinetic analysis showed that loss of cell surface proHB-EGF is maximal at 30 min after addition of TPA and that proHB-EGF is resynthesized and the initial cell surface levels are regained within 12-24 h. Loss of cell surface proHB-EGF was concomitant with appearance of 14- and 19-kDa soluble HB-EGF species in conditioned medium. Vero H cell-associated proHB-EGF is a juxtacrine growth factor for EP170.7 cells in coculture. Processing of proHB-EGF resulted in loss of juxtacrine activity and a simultaneous increase in soluble HB-EGF paracrine mitogenic activity. It was concluded that processing regulates HB-EGF bioactivity by converting it from a cell-surface juxtacrine growth factor to a processed, released soluble paracrine growth factor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579712      PMCID: PMC301256          DOI: 10.1091/mbc.6.8.967

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  41 in total

1.  Generation of transforming growth factor-alpha from the cell surface by an O-glycosylation-independent multistep process.

Authors:  J Teixido; S T Wong; D C Lee; J Massagué
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

2.  Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA.

Authors:  C A Chen; H Okayama
Journal:  Biotechniques       Date:  1988 Jul-Aug       Impact factor: 1.993

3.  Entry of diphtheria toxin linked to concanavalin A into primate and murine cells.

Authors:  J C Guillemot; A Sundan; S Olsnes; K Sandvig
Journal:  J Cell Physiol       Date:  1985-02       Impact factor: 6.384

4.  Binding properties of diphtheria toxin to cells are altered by mutation in the fragment A domain.

Authors:  E Mekada; T Uchida
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

5.  Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma.

Authors:  D M Kerbiriou; J H Griffin
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

6.  High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells.

Authors:  D Moscatelli
Journal:  J Cell Physiol       Date:  1987-04       Impact factor: 6.384

7.  Interactions between diphtheria toxin entry and anion transport in vero cells. III. Effect on toxin binding and anion transport of tumor-promoting phorbol esters, vanadate, fluoride, and salicylate.

Authors:  S Olsnes; E Carvajal; K Sandvig
Journal:  J Biol Chem       Date:  1986-02-05       Impact factor: 5.157

8.  Cloning and sequence analysis of a cDNA for rat transforming growth factor-alpha.

Authors:  D C Lee; T M Rose; N R Webb; G J Todaro
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

9.  Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells.

Authors:  J H Pierce; M Ruggiero; T P Fleming; P P Di Fiore; J S Greenberger; L Varticovski; J Schlessinger; G Rovera; S A Aaronson
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

10.  Effects of retinoids and phorbol esters on the sensitivity of different cell lines to the polypeptide toxins modeccin, abrin, ricin and diphtheria toxin.

Authors:  K Sandvig; S Olsnes
Journal:  Biochem J       Date:  1981-03-15       Impact factor: 3.857

View more
  66 in total

1.  Receptor-based antidote for diphtheria.

Authors:  Jeong-Heon Cha; Joanna S Brooke; Mee Young Chang; Leon Eidels
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

2.  Expression in mammalian cell cultures reveals interdependent, but distinct, functions for Star and Rhomboid proteins in the processing of the Drosophila transforming-growth-factor-alpha homologue Spitz.

Authors:  John C Pascall; Jane E Luck; Kenneth D Brown
Journal:  Biochem J       Date:  2002-04-15       Impact factor: 3.857

3.  The heparin-binding domain of HB-EGF mediates localization to sites of cell-cell contact and prevents HB-EGF proteolytic release.

Authors:  Robin N Prince; Eric R Schreiter; Peng Zou; H Steven Wiley; Alice Y Ting; Richard T Lee; Douglas A Lauffenburger
Journal:  J Cell Sci       Date:  2010-06-08       Impact factor: 5.285

4.  The mitogenic potential of heparin-binding epidermal growth factor in the human endometrium is mediated by the epidermal growth factor receptor and is modulated by tumor necrosis factor-alpha.

Authors:  Katya Chobotova; Mary-Elizabeth Muchmore; Janet Carver; Hyung-J Yoo; Sanjiv Manek; William J Gullick; David H Barlow; Helen J Mardon
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

5.  The role of ultraviolet irradiation and heparin-binding epidermal growth factor-like growth factor in the pathogenesis of pterygium.

Authors:  Timothy M Nolan; Nick DiGirolamo; Nitin H Sachdev; Taline Hampartzoumian; Minas T Coroneo; Denis Wakefield
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

6.  SRC-family tyrosine kinases in wound- and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells.

Authors:  Ke-Ping Xu; Jia Yin; Fu-Shin X Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

7.  Lysophosphatidic acid promoting corneal epithelial wound healing by transactivation of epidermal growth factor receptor.

Authors:  Ke-Ping Xu; Jia Yin; Fu-Shin X Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-02       Impact factor: 4.799

8.  N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration.

Authors:  E Nishi; A Prat; V Hospital; K Elenius; M Klagsbrun
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

9.  VEGF (Vascular Endothelial Growth Factor) Induces NRP1 (Neuropilin-1) Cleavage via ADAMs (a Disintegrin and Metalloproteinase) 9 and 10 to Generate Novel Carboxy-Terminal NRP1 Fragments That Regulate Angiogenic Signaling.

Authors:  Vedanta Mehta; Laura Fields; Ian M Evans; Maiko Yamaji; Caroline Pellet-Many; Timothy Jones; Marwa Mahmoud; Ian Zachary
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

10.  Amino-terminal deletion of heparin-binding epidermal growth factor-like growth factor4-127 stimulates cell proliferation but lacks insulin-like activity.

Authors:  Z Zhou; P A Harding
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.